This is the authors' abstract. We don't add key points for this paper.
The Ca 2+ release-activated Ca 2+ (CRAC) channels control many Ca 2+ -modulated physiological processes in mammals. Hyperactivating CRAC channels are known to cause several human diseases, including Stormorken syndrome. Here, we show the design of azopyrazole-derived photoswitchable CRAC channel inhibitors (designated piCRACs ), which enable optical inhibition of store-operated Ca 2+ influx and downstream signaling. Moreover, piCRAC-1 has been applied in vivo to alleviate thrombocytopenia and hemorrhage in a zebrafish model of Stormorken syndrome in a light-dependent manner.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: